Henoch-Schönlein purpura — also termed IgA vasculitis (IgAV) — is the clinical focus of this first-line protocol. The management approach is structured around early, targeted supportive intervention aimed at achieving full resolution of symptoms.
The primary target is resolution of IgAV symptoms within 6 weeks through a supportive, structured management plan.
First-line management is supportive and includes measures to maintain adequate fluid balance alongside prompt attention to any identified contributing exposures. The complete sequenced regimen — including all specific steps, thresholds, and clinical decision points — is available in the full protocol.
Adequate hydration and immediate discontinuance of any exposure to antigenic stimulants (e.g., drugs) are important cornerstone in management.
IgAV is usually self-limiting and resolves over a period of 6 weeks and management is generally supportive.
View source ↗